Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784122 | 0.88 | MAPT (0.58) | NOTUMMAPTNPSR1XBP1MEN1 | |
| SCHEMBL17783994 | 0.82 | NPC1 (0.58) | MAPTNPSR1XBP1MEN1KMT2A | |
| SCHEMBL24671304 | 0.79 | MAPT (0.72) | MAPTNPSR1XBP1MEN1KMT2A | |
| SCHEMBL29803393 | 0.79 | MAPT (0.72) | MAPTNPSR1XBP1MEN1KMT2A | |
| SCHEMBL17784020 | 0.77 | KMT2A (0.59) | MAPTNPSR1MEN1KMT2ANPC1 | |
| SCHEMBL17784110 | 0.77 | KCNQ3 (0.50) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17792180 | 0.75 | KCNQ3 (0.40) | MAPTNPSR1XBP1NPC1RAB9A | |
| SCHEMBL24670710 | 0.75 | MAPT (0.75) | MAPTNPSR1XBP1MEN1KMT2A | |
| SCHEMBL29803311 | 0.75 | MAPT (0.75) | MAPTNPSR1XBP1MEN1KMT2A | |
| SCHEMBL17784123 | 0.75 | NPC1 (0.47) | MEN1KMT2ANPC1RAB9AKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3227262-B1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC | 2017-10-19 | — | — | US | disclosed |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC | 2017-10-19 | — | — | US | disclosed |
| EP-3227262-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | Novira Therapeutics Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9597332-B2 | Sulfide alkyl compounds for HBV treatment | NOVIRA THERAPEUTICS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016089990-A1 | SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | NOVIRA THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202780-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | NOTUM 4045/4885MAPT 4829/4885NPSR1 1805/4885 |
| US-20160151375-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | NOTUM 4045/4885MAPT 4829/4885NPSR1 1805/4885 |
| US-10196351-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | NOTUM 4045/4885MAPT 4829/4885NPSR1 1805/4885 |
| US-20170298014-A1 | SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT | HAVCR2, HCCS, CBS | NOTUM 4045/4885MAPT 4829/4885NPSR1 1805/4885 |
| US-10710959-B2 | Sulfide alkyl compounds for HBV treatment | HAVCR2, HCCS, CBS | NOTUM 4045/4885MAPT 4829/4885NPSR1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.